Bristol-Myers pitches its cancer medicine pipeline

June 6, 2011 By LINDA A. JOHNSON , AP Business Writer

(AP) -- Bristol-Myers Squibb Co. executives said Monday they have more than a half-dozen drugs in testing against different cancers and could get important data on them and possibly a couple of approvals this year.

Three of those already are on the market for at least one use, the newest being drug Yervoy.

Yervoy was approved in the U.S. in March for advanced melanoma, the deadliest type of skin cancer, in patients who have failed on another therapy. European regulators recently gave it a positive review, so it should get approved there soon. It works by stimulating the immune system rather than killing cells, as older do.

Bristol's head of , Dr. Renzo Canetta, told analysts at the American Society of Clinical Oncology conference in Chicago that Yervoy's success shows such targeted immune therapies will become a standard part of .

The finding "proves the principle that immunotherapy has a role, not only in melanoma but in other tumor types," Canetta told analysts during a webcast.

He said Bristol-Myers is aiming to become a leader in immune-based cancer treatments. It has been testing Yervoy against and in combination with other treatments, and has five other, experimental immunological cancer compounds in early- to late-stage human testing.

A study testing Yervoy in newly diagnosed patients with advanced, or metastatic, melanoma, was presented at the conference Sunday and found the injected drug extended life. Among patients who got Yervoy combined with the current standard of care, a cell-killing drug called dacarbazine, 21 percent were alive after three years, compared with 12 percent for those getting dacarbazine alone.

"We rarely use the word cure in metastatic disease," Canetta said, but some patients getting Yervoy have now been followed for four years or more. "We will need even more follow-up to use this word with confidence."

Citi Investment Research analyst John Boris noted that tolerability of Yervoy was an issue in the study, due to side effects including liver inflammation. But he wrote to investors that he expects Yervoy to be come "the backbone therapy" for advanced melanoma and to produce $1.5 billion in worldwide sales in 2015, more if it also gets approved for prostate and lung cancer.

Among the other immunologic drugs, elotuzumab is probably the farthest along, with a final-stage study under way in patients with multiple myeloma, or bone marrow cancer.

A cloned antibody-based drug, it works by binding to a protein common on cancerous bone marrow cells but not on normal, healthy ones. Multiple myeloma is the second-most prevalent bone cancer, with about 40,000 new cases in the U.S. and Europe each year.

Another antibody-based compound, identified only as "anti-PD1," will soon begin midstage testing for solid tumors, starting with kidney tumors. It appears to work well in combination with Yervoy, according to the company.

Three other compounds in earlier stages of testing work by stimulating T-cells or other parts of the immune system as they bind to substances on cancer cells.

Bristol-Myers also is researching possible additional uses for Sprycel, which is approved for chronic myeloid leukemia, and Erbitux, approved for head and neck cancers.

And the company expects new data on research on brivanib, later this year on tests against liver cancer, and next year on tests against colorectal cancer. Bristol-Myers plans to apply for U.S. and European approval next year.

In early afternoon trading, Bristol-Myers shares fell 6 cents to $27.92 per share, as the broader U.S. markets all dipped.

Explore further: UCSF scientists play key role in success of Yervoy, a new cancer drug


Related Stories

UCSF scientists play key role in success of Yervoy, a new cancer drug

May 6, 2011
Yervoy is unlikely to win a contest for best named drug, but recent US Food and Drug Administration (FDA) approval for the new entrant in the battle against cancer marks the success of a novel treatment strategy, and is another ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

New study reveals breast cancer cells recycle their own ammonia waste as fuel

October 19, 2017
Breast cancer cells recycle ammonia, a waste byproduct of cell metabolism, and use it as a source of nitrogen to fuel tumor growth, report scientists from Harvard Medical School in the journal Science.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.